Literature DB >> 21149519

New approaches to rewarding pharmaceutical innovation.

Paul Grootendorst1, Aidan Hollis, David K Levine, Thomas Pogge, Aled M Edwards.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 21149519      PMCID: PMC3071389          DOI: 10.1503/cmaj.100375

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  22 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

Review 2.  Cutting the cost of drug development?

Authors:  Michael D Rawlins
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

3.  Randomized clinical trials: slow death by a thousand unnecessary policies?

Authors:  Salim Yusuf
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

4.  Clinical trials bureaucracy: unintended consequences of well-intentioned policy.

Authors:  Robert M Califf
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

5.  Owning the stuff of life.

Authors:  Gary Stix
Journal:  Sci Am       Date:  2006-02       Impact factor: 2.142

6.  The ongoing regulation of generic drugs.

Authors:  Richard G Frank
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

7.  Two ideas to increase innovation and reduce pharmaceutical costs and prices.

Authors:  Arjun Jayadev; Joseph Stiglitz
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

8.  Promoting intellectual discovery: patents versus markets.

Authors:  Debrah Meloso; Jernej Copic; Peter Bossaerts
Journal:  Science       Date:  2009-03-06       Impact factor: 47.728

9.  Before it's too late. Why synthetic biologists need an open-parts collaboration--and how to build one.

Authors:  Stephen M Maurer
Journal:  EMBO Rep       Date:  2009-08       Impact factor: 8.807

Review 10.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

View more
  4 in total

1.  Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.

Authors:  Paul Grootendorst; Ron Bouchard; Aidan Hollis
Journal:  CMAJ       Date:  2011-11-07       Impact factor: 8.262

Review 2.  Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.

Authors:  Eve A Roberts; Matthew Herder; Aidan Hollis
Journal:  CMAJ       Date:  2015-02-23       Impact factor: 8.262

3.  Harnessing the Digital Exhaust: Incorporating wellness into the pharma model.

Authors:  Justin M Wright; Graham B Jones
Journal:  Digit Biomark       Date:  2018-04-11

4.  A two-year evaluation of the minutes of Investigational New Drug committee meetings.

Authors:  Jeffrey Pradeep Raj; Nithya J Gogtay; Urmila M Thatte
Journal:  Perspect Clin Res       Date:  2020-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.